The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting ...

AL-S Pharma has released new data from the phase 2 trial evaluating its drug AP-101 in patients with amyotrophic lateral sclerosis (ALS). ALS is a progressive neurodegenerative disease that affects ...

A supplemental New Drug Application (sNDA) for Pfizer’s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) has ...

Trixeo/Breztri, is approved in the US for treatment of asthma, with regulatory filings currently under review in other major ...

AstraZeneca has entered into an exclusive licence agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel ...

Veradermics has announced positive topline results from its open-label phase 2 clinical trial (Study ‘207’) evaluating ...

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than ...

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each ...

Almirall’s submission to extend its Marketing Authorisation Application (MAA) for Ebglyss (lebrikizumab) to treat moderate-to ...

Takeda has announced new data from the two pivotal phase 3 studies of zasocitinib (TAK-279) in adults with moderate-to-severe ...

The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of ...

How do we translate individual experiences into support that helps others and create support that feels personal but remains ...